1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is 15,66€ (+2.137,14%). The median is 15,66€ (+2.137,14%).
| Buy |
4 |
| Hold |
6 |
| Sell |
1 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 0.00 | - |
| Gross profit | 0.00 | - |
| Net profit | −1.39m | 85,36% |
| EBITDA | −1.51m | 82,24% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 13.61m€ |
Number of shares | 19.34m |
52-week high/low | 883,96€ - 0,51€ |
| Dividends | No |
Beta | -2,28 |
P/E ratio | −0,01 |
PEG ratio | 0,00 |
P/B ratio | 0,07 |
P/S ratio | 0,00 |
Company profile
| Name | Kala Pharmaceuticals |
| CEO | Avi Minkowitz |
| Employees | 6 |
Discover assets
Shareholders of Kala Pharmaceuticals also invest in the following assets
